US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.53

+0.33131.22%

Post-market: 27.22-0.3162-1.15%16:10 EDT

Volume:432

Turnover:11.78K

Market Cap:2.48M

PE:- -

High:27.53

Open:27.22

Low:27.22

Close:27.20

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.43

T/O Rate:0.48%

Dividend:0.68

Dividend Rate:2.47%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

FutureChem sets final issue price for paid-in capital increase

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

NeuroThera Labs Advances Enrollment in Autism Drug Trial for SCI-210

Vogenx initiated with a Buy at Jones

SciSparc subsidiary provides update on SCI-210 trial enrollment

PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

Takeda receives FDA approval of NDA for Mimrylo

Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup

Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative

Simply Wall St.

NeuroThera Labs Hires European IR Firm to Expand Investor Reach

Oppenheimer biotech analysts hold an analyst/industry conference call

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

Becton Dickinson announces STANCE clinical trial enrollment milestone

Natera and Angiex partner in tumor testing using Signatera

Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs

Roche receives FDA approval for companion diagnostic tests for Ziihera

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/NVIB/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.5312,"timestamp":1789761600000,"preClose":27.1999,"halted":0,"volume":432,"hourTrading":{"tag":"盘后","latestPrice":27.215,"preClose":27.5312,"latestTime":"16:10 EDT","volume":6,"amount":165.1872,"timestamp":1789762204136,"change":-0.3162,"changeRate":-0.011485,"amplitude":0},"delay":0,"changeRate":0.01218019183894054,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.3313,"latestTime":"09-18 16:00:00 EDT","open":27.215,"high":27.5312,"low":27.215,"amount":11784,"amplitude":0.011625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.1999,"nav":27.179,"aum":2446135.43,"dividendRate":0.02471,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.215,"preClose":27.5312,"latestTime":"16:10 EDT","volume":6,"amount":165.1872,"timestamp":1789762204136,"change":-0.3162,"changeRate":-0.011485,"amplitude":0},"volumeRatio":0.43019315433633504},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.43019315433633504,"shares":90001,"dividePrice":0.6803,"high":27.5312,"amplitude":0.011625,"preClose":27.1999,"low":27.215,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.5312,"eps":0,"divideRate":0.02471,"volume":432,"delay":0,"ttmEps":0,"open":27.215,"prevYearClose":25,"prevWeekClose":27.3696,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":27.3696,"twentyDayClose":27.0143},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664887912","title":"FutureChem sets final issue price for paid-in capital increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887912?lang=en_us&edition=fundamental","pubTime":"2026-09-01 10:46","pubTimestamp":1788230764,"startTime":"0","endTime":"0","summary":"FutureChem Co., Ltd. ( ($KR:220100) ) has issued an announcement. FutureChem Co., Ltd., a KOSDAQ-listed radiopharmaceutical and biotech company, ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881893","title":"Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881893","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881893?lang=en_us&edition=fundamental","pubTime":"2026-09-01 07:30","pubTimestamp":1788219000,"startTime":"0","endTime":"0","summary":"An Important Step Forward for Access to LEQEMBI for Eligible Patients in CanadaTOKYO and CAMBRIDGE, Mass., Aug.  31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353756/0/en/canada-s-drug-agency-issues-final-positive-recommendation-supporting-public-reimbursement-of-leqembi-lecanemab-for-early-alzheimer-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BMED","MEDX","NVIB","IDNA","HYLG","SOCL","MCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883188","title":"NeuroThera Labs Advances Enrollment in Autism Drug Trial for SCI-210","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883188?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:37","pubTimestamp":1788208671,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs reported strong enrollment momentum in its SCI-210 clinical trial for ch...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-advances-enrollment-in-autism-drug-trial-for-sci-210?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-advances-enrollment-in-autism-drug-trial-for-sci-210?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","NVIB","HYLG","MEDX","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883886","title":"Vogenx initiated with a Buy at Jones","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883886","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883886?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:15","pubTimestamp":1788207318,"startTime":"0","endTime":"0","summary":"Jones initiated coverage of Vogenx (VOGX) with a Buy rating and $55 price target Vogenx is a clinical-stage metabolic-focused biotech company, with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NVIB","XBIX","VOGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883858","title":"SciSparc subsidiary provides update on SCI-210 trial enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883858","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883858?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207046,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC)announced that NeuroThera Labs continued advancement in participant enrollment for the clinical trial assessing NeuroThera’s SCI-210...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-subsidiary-provides-update-on-sci-210-trial-enrollment-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-subsidiary-provides-update-on-sci-210-trial-enrollment-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","BK4007","GDOC","NVIB","BK4139","MEDX","SPRC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831883","title":"PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831883","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831883?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:05","pubTimestamp":1788206710,"startTime":"0","endTime":"0","summary":"PMV Pharmaceuticals (PMVP) announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pmv-pharmaceuticals-announces-updated-ovarian-cancer-data-from-pynnacle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pmv-pharmaceuticals-announces-updated-ovarian-cancer-data-from-pynnacle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","GDOC","HYLG","PMVP","MEDX","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663588047","title":"Protagonist announces Takeda received U.S. FDA approval for MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663588047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663588047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 04:35","pubTimestamp":1788122107,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","LFSC","IDNA","TECB","PTGX","MRNX","IEIH","BK4007","MRNY","PINK","BBP","IBB","GNMX","BK4139","TAK","PSCH","BK4588","XLVX","FRTY","RSPH","SYNB","MEDI","BMED","GDOC","TBXU","IYH","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663404203","title":"Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103","url":"https://stock-news.laohu8.com/highlight/detail?id=2663404203","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663404203?lang=en_us&edition=fundamental","pubTime":"2026-08-31 03:35","pubTimestamp":1788118510,"startTime":"0","endTime":"0","summary":"Tenax Therapeutics (TENX) announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with pulmonary hyp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TENX","NVIB","BK4539","LENZ","GDOC","BK4007","MEDX","HYLG","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019703","title":"Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019703","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019703?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:52","pubTimestamp":1787964735,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an announcement. Takeda has secured U.S. FDA approval for MIMRYLO (rusfertide), a first-in-cl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","GNMX","GDOC","NVIB","PINK","MRNX","MRNY","BK4585","IDNA","FRTY","MEDI","XLVX","RSPH","SYNB","BMED","BK4588","BBP","IEIH","IYH","LFSC","TBXU","LABU","IBB","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016033","title":"Takeda receives FDA approval of NDA for Mimrylo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016033","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016033?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:00","pubTimestamp":1787958013,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia ve...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","MEDI","PINK","MRNX","NVIB","TBXU","BK4588","BK4007","IYH","SYNB","TECB","IBB","GNMX","XLVX","IEIH","IDNA","RSPH","PSCH","FRTY","BMED","LABU","GDOC","MRNY","BK4585","TAK","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663015241","title":"Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2663015241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663015241?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:22","pubTimestamp":1787952120,"startTime":"0","endTime":"0","summary":"Health-care companies fell, but not by as much as the broad market, as traders rotated into sectors less sensitive to interest-rate movements.BioNTech shares slid after the biotech firm scrapped a clinical trial for its mRNA cancer vaccine, marking the second setback this year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NVIB","XBI","BK4581","LABU","XLV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705792","title":"Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705792","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662705792?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:22","pubTimestamp":1787898153,"startTime":"0","endTime":"0","summary":"Repligen recently reported past second-quarter 2026 results that exceeded earnings and revenue expectations and raised its full-year 2026 guidance, highlighting broad year-over-year growth across filtration, chromatography, proteins, and process analytics.\nAn interesting detail is that this operational momentum, accompanied by higher full-year forecasts and rising analyst estimates, may reinforce perceptions of Repligen’s business strength across multiple bioprocessing franchises.\nWe’ll now...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0205194284.USD","LU0106261612.USD","LU0205193047.USD","NVIB","LU0012050646.USD","LU1815336091.USD","BK4121","RGEN","LU0757428866.USD","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662403754","title":"NeuroThera Labs Hires European IR Firm to Expand Investor Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2662403754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662403754?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:02","pubTimestamp":1787878968,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an announcement. NeuroThera Labs Inc., a clinical-stage biotech subsidiary of SciSparc Ltd. listed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","EPV","BBC","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662871430","title":"Oppenheimer biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662871430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662871430?lang=en_us&edition=fundamental","pubTime":"2026-08-28 02:00","pubTimestamp":1787853615,"startTime":"0","endTime":"0","summary":"Biotech Analysts, along with the Co-Director of Stanford Amyloid Cente, discuss the full results from AZN/IONS‘s CARDIO-TTRansform trial on an Anal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","NVIB","BK4585","XBIX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085942","title":"AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085942","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085942?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:01","pubTimestamp":1787835660,"startTime":"0","endTime":"0","summary":"Video webcast now availablehere OCALA, Fla., Aug.  27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)(“AIM” or the “Company”) today announced that it participated in the Virtual Inv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/27/3352073/29489/en/aim-immunotech-participates-in-the-virtual-investor-why-now-on-demand-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","NVIB","IDNA","GDOC","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662470993","title":"Becton Dickinson announces STANCE clinical trial enrollment milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2662470993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662470993?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:55","pubTimestamp":1787828139,"startTime":"0","endTime":"0","summary":"Becton Dickinson (BDX) announced a milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial eval...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/becton-dickinson-announces-stance-clinical-trial-enrollment-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/becton-dickinson-announces-stance-clinical-trial-enrollment-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4504","LU1894683348.USD","LU0878866978.SGD","LU0072461881.USD","HYLG","LU0289961442.SGD","LU0068578508.USD","IDNA","LU1854104046.USD","BK4585","GDOC","BK4588","LU1201861165.SGD","LU0006061336.USD","IHI","LU0162691827.USD","LU0433182093.SGD","LU0477156797.USD","LU1059921491.USD","LU1571399168.USD","MEDX","LU0511384066.AUD","LU0130518102.USD","LU0130103400.USD","LU1854103824.USD","LU1150488135.SGD","LU1489326972.SGD","LU1894683264.USD","IE00BFXG1179.USD","LU0985320562.USD","NVIB","LU1150488218.USD","LU0648000940.SGD","BDX","LU0266013472.USD","BK4082","LU0985489474.SGD","LU0289739343.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662221703","title":"Natera and Angiex partner in tumor testing using Signatera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662221703","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662221703?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:10","pubTimestamp":1787825446,"startTime":"0","endTime":"0","summary":"Natera (NTRA) announced a new Signatera collaboration with Angiex, a privately held biotech company developing a portfolio of Nuclear-Delivered Ant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","LU2065171311.SGD","BK4139","LU0963586101.USD","LU0106261612.USD","LU1988902786.USD","NVIB","LU0345770993.USD","GNOM","LU2065170008.USD","LU2324357040.USD","LU1064131342.USD","LU0345770308.USD","LU0012050646.USD","LU0053671581.USD","NTRA","HELX","LU2065171402.SGD","LU2264538146.SGD","LU2065731478.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662747010","title":"Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2662747010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662747010?lang=en_us&edition=fundamental","pubTime":"2026-08-27 05:47","pubTimestamp":1787780836,"startTime":"0","endTime":"0","summary":"Immatics ( ($IMTX) ) just unveiled an announcement. Immatics N.V., a Nasdaq-listed biotech company headquartered in Houston and Tübingen, focuses o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","EQR","BK4215","NVIB","XBIX","LCLG","NQmain","REZ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662874134","title":"Roche receives FDA approval for companion diagnostic tests for Ziihera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662874134","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662874134?lang=en_us&edition=fundamental","pubTime":"2026-08-27 03:00","pubTimestamp":1787770816,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that it has received FDA approval for expanded use of its PATHWAY HER2 and VENTANA HER2 Dual ISH DNA Probe Cocktail tests. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECB","IDNA","RSPH","LABU","BK4588","BMED","LFSC","IYH","NVIB","IBB","HRTS","GNMX","MRNX","XLVX","BBP","03165","CANC","RHHBY","BK4007","GDOC","IEIH","FRTY","PINK","MEDI","BK4585","TBXU","PSCH","SYNB","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797746","title":"Revolution Medicines prices Rasonque at $39,800 for 30-day supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766320,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenoc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTH","IE00BFTCPJ56.SGD","CANC","IDNA","BBP","BK4588","BK4585","FRTY","GDOC","BBH","LU0109394709.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","TBXU","XLVX","BMED","PINK","IYH","LABU","GNMX","IBB","RSPH","RVMD","TECB","IE00B4R5TH58.HKD","MEDI","IE0009355771.USD","NVIB","PSCH","LU0889565916.HKD","IE0009354923.USD","MRNY","LU0320765992.SGD","IEIH","LFSC","IE00B2B36J28.USD","MRNX","IE00BJT1NW94.SGD","SYNB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":197,"code":"91000000","status":"200"}]}}